RLMD · Relmada Therapeutics, Inc.

Current Thesis

Relmada Therapeutics’ NDV-01 re-rating thesis has failed its published price test; renewed support would require recovery of the broken market levels and delivery of the promised regulatory filing. The adjusted close of $4.12 on 2026-09-18 was below the $4.25 invalidation threshold retained in the 2026-09-06 dossier. That condition has occurred, rather than remaining a prospective risk.

As an interpretation of the price structure, the narrative is dead — the 2026-09-18 weekly close breached the remaining published shelf after the $4.75 March financing level had already failed on 2026-08-21. This describes the equity re-rating thesis, not a finding that NDV-01 has failed clinically.

The refresh adds opposing disclosures: the urology medical chief’s employment ended on 2026-09-03, while the chief executive purchased shares on 2026-09-09 and 2026-09-10. Neither disclosure establishes regulatory clearance or clinical efficacy. Sources: September 8 Form 8-K and September 11 Form 4, reproduced by StockTitan.

Bullish and bearish views on Relmada Therapeutics, Inc.

The model's bull view on Relmada Therapeutics, Inc. (RLMD), in brief: Cash supports the development program. Relmada reported $217.7 million of cash, cash equivalents and short-term investments at 2026-06-30. Its 2026-08-06 update guided funding through 2029, including completion of the NDV-01 Phase 3 RESCUE program; that runway is management’s… The bear view: The published shelf has broken. The 2026-09-18 adjusted weekly close of $4.12 breached the $4.25 threshold published before this refresh. The supplied price series records a three-month decline of 40.2% through that date. Clinical leadership changed before filing. Relmada’s… Both cases follow in full.

Bull Case

• Cash supports the development program. Relmada reported $217.7 million of cash, cash equivalents and short-term investments at 2026-06-30. Its 2026-08-06 update guided funding through 2029, including completion of the NDV-01 Phase 3 RESCUE program; that runway is management’s forecast. Q2 release
• The clinical rationale remains testable. The company’s 2026-03-09 Phase 2 interim reported an 80% complete response rate at 12 months in patients whose non-muscle invasive bladder cancer had not responded to bacillus Calmette–Guérin treatment. The subgroup denominator and confidence interval are absent from the available evidence, preventing a reliable precision assessment or a claim that Phase 3 will reproduce the result.
• Executive purchases provide an observable counterpoint. Chief executive Sergio Traversa’s 2026-09-11 Form 4 disclosed purchases of 100,000 company shares on 2026-09-09 and 100,000 on 2026-09-10. This documents insider demand; the sample is too small to support a claim about subsequent returns. Form 4

Bear Case

• The published shelf has broken. The 2026-09-18 adjusted weekly close of $4.12 breached the $4.25 threshold published before this refresh. The supplied price series records a three-month decline of 40.2% through that date.
• Clinical leadership changed before filing. Relmada’s 2026-09-08 Form 8-K states that Raj S. Pruthi’s employment as Chief Medical Officer–Urology ended on 2026-09-03. The filing supplies no reason; attributing the departure to trial problems would exceed the evidence. Form 8-K
• Manufacturing remains a regulatory dependency. The 2026-08-06 update described manufacturing work supporting an investigational new drug (IND) application expected by year-end 2026, with RESCUE initiation following clearance. It did not announce IND submission or clearance. Q2 release

Setup & Price Structure

Measured through 2026-09-18, the adjusted close was $4.12, the distance below the supplied 52-week high was 47.6%, and the 14-period relative strength index was 43.6. These observations do not establish a reversal. The $4.25 former shelf and the $4.75 March 2026 financing price are reference levels for assessing recovery; neither is current support demonstrated by the latest close.

The September executive purchases establish a specific source of demand, but the subsequent 2026-09-18 close still failed the published shelf. Current short interest, moving-average distance and a quantified retail-sentiment series are missing. The evidence therefore supports neither a crowded-long claim nor a squeeze claim.

Catalyst Calendar (next 30 days)

• 2026-09-20 through 2026-10-20: No company-confirmed catalyst was identified for this window in the available announcements. The latest release listed in Relmada’s news archive, dated 2026-09-01, concerns the already elapsed 2026-09-08 through 2026-09-10 healthcare conference. Company news archive
• 2026-12-31 — company-guided deadline: The 2026-08-06 update expects NDV-01 IND submission by year-end 2026. This later milestone belongs in the calendar because it gates the registrational program; the deadline is guidance, not a scheduled regulatory decision. Q2 release

What Would Change Our Mind

The remaining market support identified in the previous dossier has failed: a weekly close below $4.25 occurred on 2026-09-18 at $4.12. The threshold remains the historical thesis-break condition; replacing it with a lower number would obscure that outcome.

A weekly close above the March 2026 financing level of $4.75, accompanied by an announced NDV-01 IND submission, would supply evidence for a separate recovery thesis. A subsequent weekly close below $4.25 would invalidate that recovery interpretation. An explicit extension beyond 2026-12-31 would independently break the filing-timing case; absent a submission announcement by that deadline, timely execution would remain unconfirmed.

Correlation Notes

This remains a single-company clinical-development case. The 2026-08-06 manufacturing update and 2026-09-08 medical-leadership disclosure concern Relmada specifically; neither demonstrates participation in a broader oncology rally. No matched benchmark return series is available to support a numerical correlation or a sector-adjusted performance claim.